argenx shares hold as Piper Sandler keeps Overweight rating By Investing.com

On Monday, Piper Sandler maintained a positive stance on argenx SE (NASDAQ:ARGX), reiterating an Overweight rating and a price target of $522.00. The firm’s confidence in the stock is bolstered by recent survey findings indicating a favorable outlook for the company’s myasthenia gravis (gMG) treatment, Vyvgart.

The research, conducted by Spherix with 76 neurologists, suggests that new biologic treatments are broadening the gMG market. Vyvgart, in particular, is expected to gain significantly from these developments due to its perceived superior risk/reward balance. Additionally, the drug’s ongoing subcutaneous (subQ) launch is anticipated to contribute to its strong market position for the fiscal year 2024 and beyond.

The execution of ARGX’s commercial strategy in the gMG market has been recognized by healthcare professionals, which is also expected to positively influence the upcoming launch for chronic inflammatory demyelinating polyneuropathy (CIDP). Piper Sandler’s projections for worldwide Vyvgart revenue remain above consensus for 2024, reinforcing their recommendation for investors to continue buying argenx shares.

The firm’s analysis points to a robust commercial trajectory for argenx, with significant growth potential in the gMG sector. This is attributed to the company’s strategic market expansion and the successful introduction of Vyvgart to healthcare providers. Piper Sandler’s endorsement reflects a strong belief in the continued progress and financial performance of argenx in the forthcoming years.

In other recent news, biopharmaceutical company argenx SE has been making significant strides. H.C. Wainwright has reaffirmed a Buy rating for argenx, underlining the company’s successful introduction of Vyvgart for the treatment of myasthenia gravis. The firm’s confidence in argenx is also bolstered by the potential for Vyvgart’s use in additional indications and the progress within argenx’s pipeline of immunological innovations.

Argenx recently reported robust first-quarter financial results, with significant revenue growth primarily driven by the expansion of their flagship product, Vyvgart. The company’s total operating income increased by 83% compared to the same period last year, reaching $413 million. Vyvgart now serves 7,500 patients globally, contributing to a 34% increase in US patients and a 46% growth in European patient treatments.

Despite maintaining a Buy rating on the stock, H.C. Wainwright adjusted its outlook on argenx by lowering its price target slightly from $451.00 to $448.00. This decision followed argenx’s first-quarter earnings report, which showed net product sales of $398 million, slightly higher than the consensus estimate of $391 million.

InvestingPro Insights

In light of Piper Sandler’s optimistic outlook on argenx SE (NASDAQ:ARGX), InvestingPro data and tips offer additional context for investors considering this biotechnology firm. With a market capitalization of 22.69 billion USD, argenx is a significant player in the sector. Notably, the company’s revenue has shown impressive growth over the last twelve months as of Q1 2024, with an increase of 126.96%. This growth is a testament to the company’s expanding market presence, particularly as it relates to its myasthenia gravis treatment, Vyvgart.

While argenx does not currently pay a dividend to shareholders, the company holds more cash than debt on its balance sheet, which may provide a cushion for future operations and investments. Additionally, argenx has been trading at a high Price / Book multiple of 5.52, which could indicate market confidence in the company’s assets and growth trajectory. However, analysts do not anticipate the company will be profitable this year, and it has not been profitable over the last twelve months.

For investors looking for deeper insights, there are additional InvestingPro Tips available that could help navigate the investment landscape of argenx. With a strong return over the last five years and a decade, argenx has demonstrated its potential to create long-term value. To explore these insights further and to make the most informed decisions, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 6 more InvestingPro Tips available for argenx, providing a comprehensive analysis for prospective investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.